Peanut Allergy: Opportunity Analysis and Forecasts to 2027

Peanut Allergy: Opportunity Analysis and Forecasts to 2027

  • June 2018 •
  • 124 pages •
  • Report ID: 5575021 •
  • Format: PDF
Peanut Allergy: Opportunity Analysis and Forecasts to 2027

Global Peanut Allergy marketplace (8 major pharmaceutical markets - US, France, Germany, Italy, Spain, UK, Canada, and Australia) is to experience intense growth during the forecast period.It is forecasted that the Peanut Allergy market would grow over 1,700-fold between 2017 and 2027.

This incredible growth stems from the projected entry of four new peanut immunotherapy products into a previously empty marketplace. These new therapies include three oral immunotherapy (OIT) products-Aimmune Therapeutics’ AR-101, Prota Therapeutics’ PPOIT, and Camallergy’s CA-002-and one epicutaneous immunotherapy product-DBV Technologies’ Viaskin Peanut.

Peanut allergy has prevalence of 1-2.5% in developed nations and a low rate of remission-only around 20% in children. Though the specific etiology of peanut allergy is unclear, it is likely due to the interaction of genetic predisposition with environmental factors. Currently the only available strategy for managing peanut allergy long-term is avoidance and the treatment of acute reactions with injectable epinephrine. Some physicians have begun to offer their patients an investigational treatment known as experimental peanut oral immunotherapy. Though these grassroots efforts can be effective in desensitizing patients to peanut, they lack standardization and regulatory agency approval, thus making it difficult to ensure the safety of the treatment. With a complete absence of approved therapies available, peanut allergy is an indication with extremely high unmet need.

Aimmune’s AR-101, is expected to be the market leader among the four peanut immunotherapy products released during the forecast, period, capturing over 67% of the peanut allergy market in 2027, worth an estimated $3.0B. Second in sales is DBV Technologies’ Viaskin Peanut, which is projected to capture 32% of the peanut allergy market in 2027, totaling nearly $1.4B in sales. Finally, sales for Prota Therapeutics’ and Camallergy’s products, PPOIT and CA-002, together are only expected to total 1%. This estimate is based on GlobalData’s assumption that within the forecast period these therapies will each only be released in one geography-Australia and the 5EU respectively.

Growing at a compound annual growth rate (CAGR) of 111% over the 10-year forecast period, in 2027 Peanut Allergy drug sales are projected to reach over $4.5 billion. The majority of sales (88%) will come from the US. This is mainly due to the US having a large population of potential patients (estimated 3,000,000 probable diagnosed prevalent cases), an elevated expected price tag for new therapies (nearly 5-7 times that of the other geographies), and a higher expected treatment rate (based on good accessibility to allergy specialists).

The report, "Peanut Allergy: Opportunity Analysis and Forecasts to 2027", analyzes the peanut allergy treatment landscape and provides detailed insights into the market dynamics of this rapidly developing space. Analysis includes the evaluation of the clinical and commercial profiles of four late-stage pipeline candidates as well as their sales forecasts between 2017 and 2027.

The report specifically -
- Assess the current competitive landscape for peanut allergy and its evolution over the forecast period (2017-2027)
- Evaluate the significance of late-stage pipeline products entering the peanut allergy market and determine how these products will impact the future treatment landscape
- Highlight the critical unmet needs within the peanut allergy market
- Identify opportunities for growth and innovation in the peanut allergy market

- Overview of peanut allergy including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized peanut allergy therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2017 and forecast for ten years to 2027.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the peanut allergy therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global peanut allergy therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global peanut allergy therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global peanut allergy therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global peanut allergy therapeutics market from 2017-2027.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

We are very sorry, but an error occurred.
Please contact if the problem remains.